Assessing the value of medicinal innovation in an era of increasing austerity


Published: Apr 13, 2016
Keywords:
HTA innovation pharmaceutical pricing and reimbursement Greece
Mary Geitona
Abstract

In this paper an overview of the rewarding
innovation pharmaceutical regulatory systems
has been presented, focusing on the emerging
role of innovation and health technology
assessment (HTA). Ιn a time of political and
financial turmoil, benefits could be obtained
through the pooling of resources and
experiences among various countries. For this
purpose, recent major pharmaceutical reforms
in Greece have been critically discussed taking
into consideration the dynamic and complex
environment among cost containment measures
and the recent implementation of HTA in
combination with some of the critical factors
that influence today’s key decision makers, such
as the economic crisis, increasing austerity as
well as political and international pressures.

Article Details
  • Section
  • Articles
Downloads
Download data is not yet available.
Most read articles by the same author(s)